1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Clinical Trials Market

4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Clinical Trials Market Analysis and Forecast, 2018-2030
4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights
5.1. Number of Clinical Trials
5.2. Key Industry Events
5.3. COVID-19 Pandemic Impact on Industry

6. Global Clinical Trials Market Analysis and Forecast, by Phase
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Phase, 2018-2030
6.3.1. Phase I
6.3.2. Phase II
6.3.3. Phase III
6.3.4. Phase IV
6.4. Market Attractiveness Analysis, by Phase

7. Global Clinical Trials Market Analysis and Forecast, by Study Design
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Study Design, 2018-2030
7.3.1. Interventional Trials
7.3.2. Observational Trials
7.3.3. Expanded Access Trials
7.4. Market Attractiveness Analysis, by Study Design

8. Global Clinical Trials Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Indication, 2018-2030
8.3.1. Autoimmune/Inflammation
8.3.2. Pain Management
8.3.3. Cardiovascular
8.3.4. CNS Condition
8.3.5. Oncology
8.3.6. Diabetes
8.3.7. Obesity
8.3.8. Others
8.4. Market Attractiveness Analysis, by Indication

9. Global Clinical Trials Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region

10. North America Clinical Trials Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Phase, 2018-2030
10.2.1. Phase I
10.2.2. Phase II
10.2.3. Phase III
10.2.4. Phase IV
10.3. Market Value Forecast, by Study Design, 2018-2030
10.3.1. Interventional Trials
10.3.2. Observational Trials
10.3.3. Expanded Access Trials
10.4. Market Value Forecast, by Indication, 2018-2030
10.4.1. Autoimmune/Inflammation
10.4.2. Pain Management
10.4.3. Cardiovascular
10.4.4. CNS Condition
10.4.5. Oncology
10.4.6. Diabetes
10.4.7. Obesity
10.4.8. Others
10.5. Market Value Forecast, by Country, 2018-2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Phase
10.6.2. By Study Design
10.6.3. By Indication
10.6.4. By Country

11. Europe Clinical Trials Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast, by Phase, 2018-2030
11.2.1. Phase I
11.2.2. Phase II
11.2.3. Phase III
11.2.4. Phase IV
11.3.Market Value Forecast, by Study Design, 2018-2030
11.3.1. Interventional Trials
11.3.2. Observational Trials
11.3.3. Expanded Access Trials
11.4.Market Value Forecast, by Indication, 2018-2030
11.4.1. Autoimmune/Inflammation
11.4.2. Pain Management
11.4.3. Cardiovascular
11.4.4. CNS Condition
11.4.5. Oncology
11.4.6. Diabetes
11.4.7. Obesity
11.4.8. Others
11.5.Market Value Forecast, by Country/Sub-region, 2018-2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6.Market Attractiveness Analysis
11.6.1. By Phase
11.6.2. By Study Design
11.6.3. By Indication
11.6.4. By Country/Sub-region

12. Asia Pacific Clinical Trials Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Value Forecast, by Phase, 2018-2030
12.2.1. Phase I
12.2.2. Phase II
12.2.3. Phase III
12.2.4. Phase IV
12.3.Market Value Forecast, by Study Design, 2018-2030
12.3.1. Interventional Trials
12.3.2. Observational Trials
12.3.3. Expanded Access Trials
12.4.Market Value Forecast, by Indication, 2018-2030
12.4.1. Autoimmune/Inflammation
12.4.2. Pain Management
12.4.3. Cardiovascular
12.4.4. CNS Condition
12.4.5. Oncology
12.4.6. Diabetes
12.4.7. Obesity
12.4.8. Others
12.5.Market Value Forecast, by Country/Sub-region, 2018-2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6.Market Attractiveness Analysis
12.6.1. By Phase
12.6.2. By Study Design
12.6.3. By Indication
12.6.4. By Country/Sub-region

13. Latin America Clinical Trials Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Value Forecast, by Phase, 2018-2030
13.2.1. Phase I
13.2.2. Phase II
13.2.3. Phase III
13.2.4. Phase IV
13.3.Market Value Forecast, by Study Design, 2018-2030
13.3.1. Interventional Trials
13.3.2. Observational Trials
13.3.3. Expanded Access Trials
13.4.Market Value Forecast, by Indication, 2018-2030
13.4.1. Autoimmune/Inflammation
13.4.2. Pain Management
13.4.3. Cardiovascular
13.4.4. CNS Condition
13.4.5. Oncology
13.4.6. Diabetes
13.4.7. Obesity
13.4.8. Others
13.5.Market Value Forecast, by Country/Sub-region, 2018-2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6.Market Attractiveness Analysis
13.6.1. By Phase
13.6.2. By Study Design
13.6.3. By Indication
13.6.4. By Country/Sub-region

14. Middle East & Africa Clinical Trials Market Analysis and Forecast
14.1.Introduction
14.1.1. Key Findings
14.2.Market Value Forecast, by Phase, 2018-2030
14.2.1. Phase I
14.2.2. Phase II
14.2.3. Phase III
14.2.4. Phase IV
14.3.Market Value Forecast, by Study Design, 2018-2030
14.3.1. Interventional Trials
14.3.2. Observational Trials
14.3.3. Expanded Access Trials
14.4.Market Value Forecast, by Indication, 2018-2030
14.4.1. Autoimmune/Inflammation
14.4.2. Pain Management
14.4.3. Cardiovascular
14.4.4. CNS Condition
14.4.5. Oncology
14.4.6. Diabetes
14.4.7. Obesity
14.4.8. Others
14.5.Market Value Forecast, by Country/Sub-region, 2018-2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6.Market Attractiveness Analysis
14.6.1. By Phase
14.6.2. By Study Design
14.6.3. By Indication
14.6.4. By Country/Sub-region

15. Competitive Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2019
15.3. Company Profiles
15.3.1. Laboratory Corporation of America Holdings
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. IQVIA Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Syneos Health
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Parexel International Corporation
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. PPD Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Icon plc
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. Charles River Laboratories, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.8. WuXi AppTec
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
15.3.9. Medpace Holdings, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Strategic Overview
15.3.9.5. SWOT Analysis

List of Tables
Table 01: Global Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018-2030

Table 02: Global Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018-2030

Table 03: Global Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018-2030

Table 04: Global Clinical Trials Market Value (US$ Mn) Forecast, by Region, 2018-2030

Table 05: North America Clinical Trials Market Value (US$ Mn) Forecast, by Country, 2018-2030

Table 06: North America Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018-2030

Table 07: North America Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018-2030

Table 08: North America Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018-2030

Table 09: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030

Table 10: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018-2030

Table 11: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018-2030

Table 12: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018-2030

Table 13: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030

Table 14: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018-2030

Table 15: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018-2030

Table 16: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018-2030

Table 17: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030

Table 18: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018-2030

Table 19: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018-2030

Table 20: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018-2030

Table 21: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030

Table 22: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018-2030

Table 23: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018-2030

Table 24: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018-2030

List of Figures
Figure 01: Global Clinical Trials Market Value (US$ Mn) Forecast, 2018-2030

Figure 02: Global Clinical Trials Market Value Share, by Phase, 2019

Figure 03: Global Clinical Trials Market Value Share, by Indication, 2019

Figure 04: Global Clinical Trials Market Value Share, by Study Design, 2019

Figure 05: Global Clinical Trials Market Value Share, by Region, 2019

Figure 06: Global Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

Figure 07: Global Clinical Trials Market Value (US$ Mn), by Phase I, 2018-2030

Figure 08: Global Clinical Trials Market Value (US$ Mn), by Phase II, 2018-2030

Figure 09: Global Clinical Trials Market Value (US$ Mn), by Phase III, 2018-2030

Figure 10: Global Clinical Trials Market Value (US$ Mn), by Phase IV, 2018-2030

Figure 11: Global Clinical Trials Market Attractiveness Analysis, by Phase, 2020-2030

Figure 12: Global Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

Figure 13: Global Clinical Trials Market Value (US$ Mn), Interventional Trials, 2018-2030

Figure 14: Global Clinical Trials Market Value (US$ Mn), Observational Trials, 2018-2030

Figure 15: Global Clinical Trials Market Value (US$ Mn), Expanded Access Trials, 2018-2030

Figure 16: Global Clinical Trials Market Attractiveness Analysis, by Study Design, 2020-2030

Figure 17: Global Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

Figure 18: Global Clinical Trials Market Value (US$ Mn), Autoimmune /Inflammation, 2018-2030

Figure 19: Global Clinical Trials Market Value (US$ Mn), Pain Management, 2018-2030

Figure 20: Global Clinical Trials Market Value (US$ Mn), Cardiovascular, 2018-2030

Figure 21: Global Clinical Trials Market Value (US$ Mn), CNS Condition, 2018-2030

Figure 22: Global Clinical Trials Market Value (US$ Mn), Oncology, 2018-2030

Figure 23: Global Clinical Trials Market Value (US$ Mn), Diabetes, 2018-2030

Figure 24: Global Clinical Trials Market Value (US$ Mn), Obesity, 2018-2030

Figure 25: Global Clinical Trials Market Value (US$ Mn), Others, 2018-2030

Figure 26: Global Clinical Trials Market Attractiveness Analysis, by Indication, 2020-2030

Figure 27: Global Clinical Trials Market Value Share Analysis, by Region, 2019 and 2030

Figure 28: Global Clinical Trials Market Attractiveness Analysis, by Region, 2020-2030

Figure 29: North America Clinical Trials Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030

Figure 30: North America Clinical Trials Market Value Share (%), by Country, 2019 and 2030

Figure 31: North America Clinical Trials Market Attractiveness, by Country, 2020-2030

Figure 32: North America Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

Figure 33: North America Clinical Trials Market Attractiveness Analysis, by Phase, 2020-2030

Figure 34: North America Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

Figure 35: North America Clinical Trials Market Attractiveness Analysis, by Study Design, 2020-2030

Figure 36: North America Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

Figure 37: North America Clinical Trials Market Attractiveness Analysis, by Indication, 2020-2030

Figure 38: Europe Clinical Trials Market Value (US$ Mn) Forecast, 2018-2030

Figure 39: Europe Clinical Trials Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 40: Europe Clinical Trials Market Attractiveness Analysis, by Country/Sub-region, 2020-2030

Figure 41: Europe Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

Figure 42: Europe Clinical Trials Market Attractiveness Analysis, by Phase, 2020-2030

Figure 43: Europe Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

Figure 44: Europe Clinical Trials Market Attractiveness Analysis, by Study Design, 2020-2030

Figure 45: Europe Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

Figure 46: Europe Clinical Trials Market Attractiveness Analysis, by Indication, 2020-2030

Figure 47: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, 2018-2030

Figure 48: Asia Pacific Clinical Trials Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 49: Asia Pacific Clinical Trials Market Attractiveness Analysis, by Country/Sub-region, 2020-2030

Figure 50: Asia Pacific Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

Figure 51: Asia Pacific Clinical Trials Market Attractiveness Analysis, by Phase, 2020-2030

Figure 52: Asia Pacific Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

Figure 53: Asia Pacific Clinical Trials Market Attractiveness Analysis, by Study Design, 2020-2030

Figure 54: Asia Pacific Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

Figure 55: Asia Pacific Clinical Trials Market Attractiveness Analysis, by Indication, 2020-2030

Figure 56: Latin America Clinical Trials Market Value (US$ Mn) Forecast, 2018-2030

Figure 57: Latin America Clinical Trials Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 58: Latin America Clinical Trials Market Attractiveness Analysis, by Country/Sub-region, 2020-2030

Figure 59: Latin America Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

Figure 60: Latin America Clinical Trials Market Attractiveness Analysis, by Phase, 2020-2030

Figure 61: Latin America Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

Figure 62: Latin America Clinical Trials Market Attractiveness Analysis, by Study Design, 2020-2030

Figure 63: Latin America Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

Figure 64: Latin America Clinical Trials Market Attractiveness Analysis, by Indication, 2020-2030

Figure 65: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, 2018-2030

Figure 66: Middle East & Africa Clinical Trials Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 67: Middle East & Africa Clinical Trials Market Attractiveness Analysis, by Country/Sub-region, 2020-2030

Figure 68: Middle East & Africa Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

Figure 69: Middle East & Africa Clinical Trials Market Attractiveness Analysis, by Phase, 2020-2030

Figure 70: Middle East & Africa Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

Figure 71: Middle East & Africa Clinical Trials Market Attractiveness Analysis, by Study Design, 2020-2030

Figure 72: Middle East & Africa Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

Figure 73: Middle East & Africa Clinical Trials Market Attractiveness Analysis, by Indication, 2020-2030

Figure 74: Global Clinical Trials Market Share Analysis, by Company, 2019